CAG
ADMA icon

Csenge Advisory Group’s ADMA Biologics ADMA Stock Holding History

Csenge Advisory Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,000
Closed -$44K – 392
2020
Q2 		$44K Hold
15,000
– – 0.01% 368
2020
Q1 		$43K Hold
15,000
– – 0.01% 293
2019
Q4 		$60K Sell
15,000
-8,000
-35% -$34.9K 0.02% 285
2019
Q3 		$102K Buy
+23,000
New +$96.1K 0.03% 266

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Csenge Advisory Group's ADMA Position: Q3 2020 in Review

Csenge Advisory Group sold out of ADMA Biologics (ADMA) in Q3 2020, closing a stake of 15,000 shares — an estimated $44K sold.

Csenge Advisory Group first reported a position in ADMA in Q3 2019 and held it in 4 quarters. The position peaked at $102K in Q3 2019. 95 funds tracked by Wall St. Rank hold ADMA as of Q3 2020.

  • Csenge Advisory Group reported no remaining ADMA Biologics position as of Q3 2020 after selling out during the quarter.
  • Csenge Advisory Group sold 15,000 ADMA Biologics shares in Q3 2020, an estimated $44K.
  • Csenge Advisory Group first reported a position in ADMA Biologics in Q3 2019 and held it in 4 quarters.
  • Csenge Advisory Group's ADMA Biologics position peaked at $102K in Q3 2019.
  • 95 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2020.

Based on Csenge Advisory Group's 13F filing for Q3 2020, filed 9 Nov 2020.